Month: March 2025

Meet with Christopher Kata and Chris Hamelin at the SCDM EMEA meeting in Brussels, Belgium!

03/31/2025

Meet with Christopher Kata, Director of Sales & Marketing and Chris Hamelin, President April 9th – 11th, 2025 at the SCDM EMEA meeting being held in Brussels, Belgium! If you’re attending be sure to to reach out to Christopher and Chris to schedule a one on meeting or just drop by booth at your convenience!…

Read More

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

03/28/2025

Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from the Company’s Phase 1/1b clinical trial of soquelitinib for the…

Read More

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

03/27/2025

Excerpt from the Press Release: BOSTON, March 13, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase I clinical trial has unanimously approved opening of the fourth cohort of patients based on…

Read More

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

03/26/2025

Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models Excerpt from the Press Release: BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Corvus…

Read More

Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions

03/25/2025

New water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaks Excerpt from the Press Release: BOSTON, MASSACHUSETTS, March 12, 2025 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, unveiled a potential game-changer in…

Read More

A Vaccine For Pancreatic Cancer Continues To Show Promise

03/24/2025

Excerpt from the Press Release: Pancreatic cancer is notoriously difficult to treat, and about 90% of diagnosed patients die from the disease. A team at Memorial Sloan Kettering has been working to improve those outcomes by developing a new mRNA vaccine for pancreatic cancer. A few years ago, the team embarked on a small trial…

Read More

SKYLINEDX ANNOUNCES NEW STUDY DEMONSTRATING ENHANCED RISK STRATIFICATION FOR SENTINEL LYMPH NODE BIOPSY IN HEAD AND NECK MELANOMA USING THE ADVANCED MERLIN CP-GEP TEST

03/21/2025

Excerpt from the Press Release: ROTTERDAM, Netherlands and SAN DIEGO, March 12, 2025 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology and, inflammatory and infectious diseases, proudly announces the publication of a groundbreaking study titled “Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head…

Read More

Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer

03/20/2025

Excerpt from the Press Release: AUSTIN, Texas & PHILADELPHIA–(BUSINESS WIRE)–Faeth Therapeutics (Faeth), a clinical-stage biotechnology company focused on metabolism, and The GOG Foundation, Inc. (GOG-F), a not-for-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and translational scientific research in the field of gynecologic malignancies, today announced the first…

Read More

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

03/19/2025

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, will highlight progress across its clinical pipeline, including continued advancement of…

Read More

The Essential Role of TrialStat’s Project Managers and Technical Support in Electronic Data Capture for Clinical Trials

03/18/2025

In clinical trials, the accuracy, efficiency, and integrity of data collection are paramount. Electronic Data Capture (EDC) vendors play a crucial role in ensuring these standards are met, and two key groups that facilitate this are project managers and technical support teams. Together, they help sponsors navigate the complexities of clinical trials, from initial setup…

Read More